Valion Bio, Inc. filed a Form 8-K with the SEC on September 23, 2026, disclosing the appointment of Dean Zikria as Interim Chief Executive Officer, a board resignation, and related committee changes, all effective as of September 17 or September 22, 2026.
Key Highlights
- Interim CEO appointment: Dean Zikria was appointed Interim Chief Executive Officer of Valion Bio, Inc. effective September 22, 2026, while remaining a member of the Board of Directors.
- Monthly consulting fee: Under a Consulting Agreement, Mr. Zikria is entitled to receive $23,333 per month.
- RSU grants: Mr. Zikria is entitled to receive 50,000 RSUs upon appointment and another 50,000 RSUs upon a stockholder-approved increase in the Company's equity plan, subject to Special Committee approval.
- Board resignation: Sheryle Bolton resigned from the Board effective September 17, 2026; the filing states the resignation was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.
- New committee chairs: Thomas Jensen was appointed Chair of the Board and Chair of the Compensation Committee; Jared Malbin was appointed Chair of the Audit and Risk Committee, both effective September 17, 2026.
- Agreement term: The Consulting Agreement terminates on January 22, 2027, unless mutually extended by the parties up to twelve months from its effective date.
Valion Bio Leadership Overhaul: Zikria Takes Interim CEO Role
According to the filing, Valion Bio, Inc. (NASDAQ:VBIO), a Delaware corporation headquartered at 1305 E. Houston Street, Building 1, Suite 311, San Antonio, Texas 78205, appointed Dean Zikria, age 58, as Interim Chief Executive Officer on September 22, 2026. Mr. Zikria has served as a director on the Company's Board since July 10, 2019. The filing states he brings experience in allergy, asthma, and other chronic diseases, along with backgrounds in strategic planning and mergers and acquisitions.
The filing details Mr. Zikria's professional history, noting that since August 2019 he has served as Founder, CEO, and Chairman of Mind Machine LLC, a Silicon Valley-based marketing and advertising agency focused on the MedTech industry. He previously served as Chief Commercial Officer at Intuity Medical Inc. from June 1, 2021, until January 2023, and as CEO of Spirosure Inc. from 2014 to 2017. He also previously served as head of global marketing for Johnson and Johnson's Animas Corporation and as head of strategy for Pfizer Pharmaceuticals U.S. Cardiovascular Unit, which the filing describes as a division with approximately $7 billion in annual revenues.
Under the Consulting Agreement dated September 22, 2026, the filing discloses that Mr. Zikria is classified as an independent contractor, not an employee or agent of the Company. In addition to the monthly fee and RSU grants, he may be eligible for a cash bonus upon closing of a strategic transaction, defined in the filing as "a reverse merger, a merger, or acquisition," at the discretion of the Board or the Compensation Committee. The filing also notes that Mr. Zikria was removed from the Audit and Risk Committee, Compensation Committee, and Nominations and Corporate Governance Committee while serving as Interim CEO. The Company reported no family relationships between Mr. Zikria and any directors or executive officers.
What Was Disclosed
Valion Bio disclosed the appointment of Dean Zikria as Interim CEO under a consulting arrangement, the resignation of board member Sheryle Bolton, and new committee chair assignments for Thomas Jensen and Jared Malbin, all occurring between September 17 and September 22, 2026.



Please wait processing your request...